Eipico, a pharmaceutical company from Egypt, will build a $30 million biopharmaceutical manufacturing site in Saran, the Karaganda region, according to Kazakh Invest.
The new factory will produce biosimilars and antitumor drugs under international GMP standards. All these medicines are meant to be supplied to domestic and some neighboring markets. Once the project is implemented, 150 to 200 jobs will be created.
Biosimilars are biological agents highly similar to particular biologics. When a drug patent expires, various pharma companies receive the right to reproduce this drug on their own. There is no difference in safety, efficacy and quality between biosimilars...